"The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.
Caution should be exercised to prevent inadvertent overdosage with PLATINOL-AQ. Acute overdosage with this drug may result in kidney failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, intractable nausea and vomiting and/or neuritis. In addition, death can occur following overdosage.
No proven antidotes have been established for PLATINOL-AQ overdosage. Hemodialysis, even when initiated four hours after the overdosage, appears to have little effect on removing platinum from the body because of PLATINOL-AQ's rapid and high degree of protein binding. Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur.
PLATINOL-AQ is contraindicated in patients with preexisting renal impairment. PLATINOL-AQ should not be employed in myelosuppressed patients, or in patients with hearing impairment.
PLATINOL-AQ is contraindicated in patients with a history of allergic reactions to PLATINOL-AQ or other platinum-containing compounds.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/24/2012
Additional Platinol-AQ Information
Platinol-AQ - User Reviews
Platinol-AQ User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.